Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Stage III melanoma (after surgery), drawn from the whole corpus: 20 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Most stage IIIA patients would never have relapsed, so a year of immunotherapy with lifelong endocrine side effects in some is given to many who do not need it.
Nothing recorded yet.
Background: Neoadjuvant / adjuvant / perioperative. Also on OnCo: Treatment journeys · Survivorship planner.
No biomarker yet tells who can safely skip adjuvant therapy; circulating tumour DNA trials are testing this.
Overall survival gains from adjuvant PD-1 blockade are small because relapsing patients receive the same drugs later.
Nothing recorded yet.
Background: Neoadjuvant / adjuvant / perioperative. Also on OnCo: Treatment journeys · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 18 changes by month →When this page itself was last checked or edited.
RFS and DMFS significantly improved (HRs pending presentation).
A milestone in how this cancer is treated.
RFS not improved.
12-month EFS 83.
A milestone in how this cancer is treated.